Axio was founded in 2008 by Leo Mavely, a bioengineer to develop novel biopolymer platform based products for wound care. Axio has the distinction to be the first company from India to design, develop and commercialize an Emergency Haemostat for Trauma care. Vision of Axio is to develop affordable, high impact medical products that can solve unmet healthcare needs of emerging markets. Controlling life-threatening bleeding continues to be the major cause of death from traumatic injuries. Axiostat® is its flagship product developed to reduce the mortality due to traumatic bleeding. Axio is a ISO 13485 certified company with an experienced team focused on bringing high-impact medical products to market.